MedTrace Logo

Study of Gynecological Follow-up of Patients With Autoimmune Disease or Inflammatory Rheumatism

NCT05961267 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 318

Last updated 2024-09-19

No results posted yet for this study

Summary

Autoimmune diseases are the consequence of an abnormality of the immune system, leading it to attack components of our own body. They have a wide variety of presentations. They preferentially affect women, and often at a young age. Systemic lupus erythematosus, for example, most often occurs between the ages of 15 and 40.

Inflammatory rheumatism, such as spondyloarthritis or rheumatoid arthritis, is less prevalent in women, but also affects young people, and is particularly common.

Several disease-modifying treatments exist, depending on the severity and evolutivitý of the disease. Some are contraindicated or not recommended during pregnancy and therefore require supervision of pregnancy plans.

In addition, some treatments have an immunosuppressive activitý, which implies an annual screening of cervical lesions by cervico-uterine smear.

In this context, an adapted gynecological follow-up seems indispensable. The rheumatologist and the internist physician have a crucial role in advising and referring patients to their gynecological colleagues.

Studying the qualitý of this gynecological follow-up in a cohort of patients with autoimmune disease or inflammatory rheumatism is of major interest.

Conditions

  • Arthritis, Rheumatoid
  • Spondylitis, Ankylosing
  • Lupus Erythematosus, Systemic
  • Scleroderma, Systemic
  • Sjogren's Syndrome
  • Mixed Connective Tissue Disease

Interventions

BEHAVIORAL

Questionnaire

A gynecological follow-up questionnaire will be proposed to patients with one of the above mentioned pathologies. This is a standardized questionnaire specifically designed for this study.

Sponsors & Collaborators

  • University Hospital, Bordeaux

    lead OTHER

Principal Investigators

  • Christophe RICHEZ, Prof · University Hospital, Bordeaux

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-24
Primary Completion
2024-06-28
Completion
2024-06-28

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05961267 on ClinicalTrials.gov